NAC & Cardiovascular Health

NAC has two distinct cardiovascular stories. The older story is nitrate tolerance: patients on continuous nitroglycerin therapy lose the hemodynamic benefit within 24–48 hours because the sulfhydryl groups that convert organic nitrates to nitric oxide get depleted. NAC donates the missing thiols and restores efficacy — the classic observations of Packer 1987 and Horowitz 1988. The newer story is the NACIAM trial (Pasupathy 2017, Circulation), which randomized STEMI patients undergoing primary PCI to high-dose IV NAC alongside low-dose nitroglycerin and showed a 5.5 percentage point absolute reduction in cardiac-MRI infarct size and a doubling of myocardial salvage. Beyond these two flagship uses, NAC lowers homocysteine, modestly improves endothelial function and blood pressure, and has nuanced effects on lipids. The most important practical caution for patients is the genuine risk of symptomatic hypotension when NAC is combined with chronic nitrate therapy.

Cardiovascular Mechanism: Thiols, Nitric Oxide, and Homocysteine
Homocysteine Lowering
Hypertension and Endothelial Function
Atherosclerosis and Oxidized LDL
Acute Myocardial Infarction — the NACIAM Trial
Heart Failure
Nitrate Tolerance Prevention
Type 2 Diabetes and Metabolic Syndrome
Dyslipidemia
Peripheral Artery Disease
Dosing
Safety and the Nitroglycerin Interaction
References
Connections
Featured Videos

Cardiovascular Mechanism: Thiols, Nitric Oxide, and Homocysteine

Cardiovascular disease is now understood as a disease of oxidative imbalance as much as cholesterol transport. In atherosclerosis, hypertension, diabetes, and heart failure, superoxide production by NADPH oxidase and uncoupled endothelial NO synthase (eNOS) outpaces antioxidant defenses. Superoxide destroys nitric oxide in a diffusion-limited reaction to form peroxynitrite, producing three downstream problems: loss of endothelial vasodilation, oxidation of LDL into its atherogenic oxLDL form, and activation of NF-kB-driven inflammation.

NAC addresses this at multiple levels:

Glutathione replenishment — cysteine is the rate-limiting substrate for glutathione synthesis.
Nitric oxide preservation — by lowering superoxide, NAC preserves endothelial NO bioavailability; by forming S-nitroso-NAC, it provides an NO-donating reservoir that resists tolerance.
Homocysteine lowering — NAC's free thiol displaces homocysteine from its protein-bound and disulfide forms into free reduced homocysteine, which is renally cleared. This is a mechanism distinct from folate/B12 remethylation.
Disulfide reduction — NAC cleaves plasma protein-cysteine and homocysteine-cysteine disulfides, restoring reduced cysteine pools that support eNOS cofactor recycling.

Homocysteine Lowering

Elevated homocysteine is an independent cardiovascular risk factor that causes endothelial dysfunction, promotes LDL oxidation, and activates thrombogenic pathways. Folate / B12 supplementation produces roughly 25% reductions but has failed to reduce hard cardiovascular endpoints in multiple trials. NAC works by a different mechanism (disulfide displacement rather than methylation).

Hildebrandt 2015 (Am J Clin Nutr): Two double-blind placebo-controlled trials in middle-aged unmedicated men. 4 weeks of oral NAC 1,800 mg/day significantly reduced plasma total homocysteine (~12% reduction vs ~4% on placebo). Systolic BP fell in both groups; diastolic fell in hyperlipidemic men.
Wiklund 1996 (Atherosclerosis): NAC treatment lowered plasma homocysteine without affecting lipoprotein(a).
Ventura 1999 (Eur J Clin Invest): single IV NAC dose reduced plasma homocysteine by increasing urinary thiol excretion within hours — direct confirmation of the disulfide-displacement mechanism.
Friedman 2003 (Am J Kidney Dis): hemodialysis patients (chronically hyperhomocysteinemic); NAC significantly reduced total homocysteine.

Typical effect: 10–45% reduction in total plasma homocysteine at 1,200–2,400 mg/day, with larger reductions in patients with higher baseline homocysteine.

Hypertension and Endothelial Function

The core lesion in primary hypertension is endothelial dysfunction — inadequate NO release relative to vasoconstrictor tone. NAC's antioxidant action prevents NO destruction by superoxide.

Martina 2008 (Diabetes Care): 6-month double-blind trial in 24 male hypertensive type 2 diabetics. NAC 1,200 mg/day + L-arginine 1.2 g/day significantly lowered systolic and diastolic BP (effect size ~5–8 mmHg systolic), improved post-ischemic vasodilation, and reduced ICAM-1, VCAM-1, and E-selectin.
Andrews 2001 (JACC): intracoronary and intrafemoral NAC in 16 patients during catheterization. Acetylcholine-mediated coronary blood flow rose 36 ± 11%; epicardial diameter shifted from constriction to dilation. Direct demonstration that NAC rescues endothelium-dependent vasodilation.
Hildebrandt 2015: systolic BP fell on 1,800 mg/day in both normolipidemic and hyperlipidemic men.

Atherosclerosis and Oxidized LDL

Oxidized LDL (oxLDL) is the immunogenic, atherogenic form of LDL; scavenger-receptor uptake by macrophages produces foam cells. Carotid intima-media thickness (cIMT) is the standard non-invasive measure of subclinical atherosclerosis.

Lu 2015 (Sci Rep): NAC inhibited in vivo oxidation of native LDL and reduced ROS formation from oxLDL.
Martina 2008: 6-month NAC + L-arginine reduced carotid IMT during endothelial post-ischemic vasodilation assessment.
Pereira 2022 (Atherosclerosis): 6-month NAC slowed (but did not reverse) atherosclerotic lesion progression in aging LDLr-/- mice; preserved anti-inflammatory M2 macrophage polarization.
Faghfouri 2023 review: animal data consistent for slowed atherosclerosis; human data limited and inconsistent.

Acute Myocardial Infarction — the NACIAM Trial

NACIAM (Pasupathy 2017, Circulation)

Landmark randomized, double-blind, multicenter trial in 112 STEMI patients undergoing primary PCI. IV high-dose NAC (29 g over 2 days) plus background low-dose nitroglycerin versus placebo plus low-dose nitroglycerin.

Absolute 5.5% reduction in cardiac-MRI-assessed infarct size (11.0% vs 16.5%, p=0.02)
Myocardial salvage approximately doubled (60% vs 27%, p<0.01)
More rapid chest pain resolution
Sustained infarct-size reduction at 3 months
Favorable clinical outcomes at 2 years

Other Acute MI and Reperfusion Data

Arstall 1995 (Circulation): IV NAC + nitroglycerin + streptokinase in acute MI improved LV preservation and reduced oxidative stress.
Koramaz 2006 (Heart Vessels): IV NAC in CABG significantly lowered ROS, TNF-alpha, and CK-MB at 6 and 12 hours.
Wang 2018 meta-analysis (J Thorac Cardiovasc Surg): 29 RCTs / 2,486 cardiac surgery patients. NAC did not significantly reduce mortality, AKI, or heart failure overall, but subgroups showed reduced oxidative markers and atrial fibrillation.

Heart Failure

Talasaz 2021 (Ir J Med Sci): 55 stable NYHA II-III systolic HF patients, oral NAC 600 mg BID vs placebo for 12 weeks. Significantly improved LV systolic function (ejection fraction, Tei index).
Giam 2016 (Physiol Rep mouse model): NAC 40 mg/kg/day for 8 weeks reduced perivascular and interstitial cardiac fibrosis by 40% and 57% respectively.
Mehra 2013 cardiorenal pilot: improved endothelial function and lowered BNP in cardiorenal syndrome.

Nitrate Tolerance Prevention

Continuous nitrate therapy produces rapid tolerance — loss of hemodynamic and antianginal effect within 24–48 hours — because the sulfhydryl groups that catalyze conversion of organic nitrates to NO become depleted. NAC donates the missing thiols.

Packer 1987 (NEJM): foundational demonstration. In congestive heart failure, IV NTG's hemodynamic benefit was largely lost at 48 hours; adding NAC restored the response. Established the sulfhydryl-depletion hypothesis of tolerance.
Horowitz 1988 (Circulation): 46 patients with severe unstable angina refractory to conventional therapy. NTG + IV NAC (5 g every 6 h) had significantly lower acute MI rates than NTG alone (3 vs 10 patients, p=0.013). Tradeoff: symptomatic hypotension in 7 vs 0.
Pizzulli 1997 (JACC): long-term transdermal NTG with/without NAC in unstable angina — NAC-containing arms had improved clinical outcomes.
Gibbs and Pizzulli 1997 (Am J Cardiol): NAC attenuated nitroglycerin tolerance in stable angina with preserved LV function.

Type 2 Diabetes and Metabolic Syndrome

Results are genuinely mixed — oxidative stress is a valid target, but oral NAC has shown inconsistent effects on HbA1c.

Szkudlinska 2016 (J Diabetes Complications): negative RCT in 13 T2D subjects; no improvement in glucose tolerance or insulin release.
Sekhar 2022 GlyNAC pilot: glycine + NAC for 14 days in T2D improved glutathione synthesis, mitochondrial fuel oxidation, and insulin resistance. Suggests glycine co-supplementation is necessary for glycemic effect.
Treweeke 2012 (Diabetologia): NAC inhibited platelet-monocyte conjugation in T2D patients with depleted intraplatelet glutathione — a vascular-protective effect independent of glycemic control.
Martina 2008: NAC + L-arginine in hypertensive T2D improved endothelial function and lowered BP.
Hosseini 2022 (Complement Ther Med): 76 metabolic-syndrome patients, NAC 1,800 mg/day for 12 weeks. Significant reductions in FPG, insulin, HOMA-IR, and CRP. HDL rose. No change in BP or triglycerides.

Summary: oral NAC monotherapy does not reliably improve HbA1c but does improve vascular complications (endothelial function, platelet reactivity). GlyNAC combinations look more promising for insulin sensitivity per se.

Dyslipidemia

NAC's lipid effect is modest but real, with the most consistent signal being HDL elevation.

De Flora 1985 (Drugs Exp Clin Res): 10 hyperlipidemic patients on NAC 1,200–3,600 mg/day; HDL-cholesterol rose dose-dependently, with the highest dose producing ~10 mg/dL (16.2%) increase.
Hosseini 2022: 1,800 mg/day raised HDL but did not change LDL or triglycerides in metabolic syndrome.
Animal studies show triglyceride and LDL reduction in STZ-diabetic rats, but the human signal is primarily HDL-elevating.

Peripheral Artery Disease

Evidence is thin and mostly mechanistic:

Wilmink 1999 (Arterioscler Thromb Vasc Biol): NAC co-administration with methionine loading prevents endothelial dysfunction induced by acute hyperhomocysteinemia.
Andrews 2001: femoral (peripheral) vasodilation was potentiated by NAC (p=0.001).
Wiklund 1996: NAC-mediated homocysteine lowering is relevant to PAD risk.

Dosing

Oral

600 mg/day — minimum dose with documented antioxidant effect; common entry dose.
1,200–1,800 mg/day — the evidence-based cardiovascular range (Hildebrandt 1,800; Horowitz long-term regimens; Talasaz 1,200; Hosseini 1,800). Divided BID or TID.
2,400 mg/day — upper end of routine supplementation; used in some homocysteine-lowering protocols.
Up to 3,000 mg/day used safely in chronic respiratory and psychiatric trials.

Intravenous (Hospital Only)

NACIAM / acute MI protocol: 29 g total over 2 days alongside low-dose nitroglycerin.
Cardiac surgery: 50–150 mg/kg loading then 50 mg/kg/day infusion.

Oral bioavailability of intact NAC is ~4% for the reduced form; total NAC ~9%. Low intact-molecule figures are not a failure mode — first-pass hepatic deacetylation channels the dose directly to cysteine and glutathione, which are the active downstream species.

Safety and the Nitroglycerin Interaction

The Critical Cardiovascular Caution

Because NAC potentiates nitrate-derived NO, combined use with nitroglycerin or long-acting nitrates can produce severe symptomatic hypotension and worse nitrate headache. Horowitz 1988 reported symptomatic hypotension in 7 of 23 unstable-angina patients on NTG + NAC versus 0 of 23 on NTG alone. Patients on chronic nitrate therapy who are considering NAC must know this and ideally have blood pressure monitored when starting the combination.

Other Safety Points

GI side effects — nausea, vomiting, diarrhea, epigastric pain — in up to ~23% of oral users. The sulfur smell contributes to nausea.
Anaphylactoid reactions with IV (rash, flushing, bronchospasm, hypotension) are histamine-mediated. Manage by slowing infusion.
No clinically significant bleeding signal at standard doses; mild antiplatelet activity exists but rarely matters.
Caution with inhaled/nebulized NAC in asthma.
Routine contrast-induced nephropathy prophylaxis is no longer recommended based on the ACT and PRESERVE trials.

References

Hildebrandt W, Sauer R, Bonaterra G, Dugi KA, Edler L, Kinscherf R. Oral NAC reduces plasma homocysteine regardless of lipid or smoking status: RCT. Am J Clin Nutr 2015;102(5):1014–1024. PMID 26447155.
Wiklund O, Fager G, Andersson A, et al. NAC treatment lowers plasma homocysteine but not serum Lp(a). Atherosclerosis 1996;119(1):99–106. PMID 8929261.
Friedman AN, Bostom AG, Laliberty P, Selhub J, Shemin D. Effect of NAC on plasma total homocysteine in hemodialysis: RCT. Am J Kidney Dis 2003;41(2):442–446. PMID 12552508.
Ventura P, Panini R, Pasini MC, Scarpetta G, Salvioli G. NAC reduces homocysteine plasma levels by increasing thiol urinary excretion. Pharmacol Res 1999;40(4):345–350. PMID 10527647.
Martina V, Masha A, Gigliardi VR, et al. Long-term NAC and L-arginine reduce endothelial activation and SBP in hypertensive T2D. Diabetes Care 2008;31(5):940–944. PMID 18268065.
Andrews NP, Prasad A, Quyyumi AA. NAC improves coronary and peripheral vascular function. J Am Coll Cardiol 2001;37(1):117–123. PMID 11153725.
Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in CHF. NEJM 1987;317(13):799–804. PMID 3114637.
Horowitz JD, Henry CA, Syrjanen ML, et al. Combined nitroglycerin and NAC in unstable angina. Circulation 1988;77(4):787–794. PMID 3127076.
Pizzulli L, Hagendorff A, Zirbes M, et al. Transdermal NTG or NAC in unstable angina. J Am Coll Cardiol 1997;29(5):941–947. PMID 9120179.
Pasupathy S, Tavella R, Grover S, et al. Early NAC with nitrate therapy in primary PCI for STEMI (NACIAM). Circulation 2017;136(10):894–903. PMID 28634219.
Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. NAC with nitroglycerin and streptokinase for acute MI. Circulation 1995;92(10):2855–2862. PMID 7586252.
Koramaz I, Pulathan Z, Usta S, et al. Cold-blood cardioplegia enriched with NAC in CABG. Heart Vessels 2006;21(1):42–47. PMID 16440148.
Wang G, Bainbridge D, Martin J, Cheng D. NAC in cardiac surgery: meta-analysis. J Cardiothorac Vasc Anesth 2011;25(2):268–275. PMID 20638862.
Talasaz AH, Khalili H, Jenab Y, et al. Oral NAC improves heart function in stable HF. Ir J Med Sci 2021;191(4):1691–1698. PMID 34727343.
Giam B, Chu PY, Kuruppu S, et al. NAC attenuates cardiac fibrosis in HF mouse model. Physiol Rep 2016;4(7):e12757. PMID 27081162.
Lu SC, Huang HY. NAC inhibits in vivo oxidation of native LDL. Sci Rep 2015;5:16339.
De Flora S, Grassi C, Carati L. Dose-related increase of HDL-cholesterol after NAC. Drugs Exp Clin Res 1985;11(12):863–867. PMID 8108311.
Szkudlinska MA, von Frankenberg AD, Utzschneider KM. NAC does not improve glucose tolerance in T2D. J Diabetes Complications 2016;30(4):618–622. PMID 26922582.
Treweeke AT, Winterburn TJ, Mackenzie I, et al. NAC inhibits platelet-monocyte conjugation in T2D. Diabetologia 2012;55(11):2920–2928.
Hosseini H, Naderi-Behdani F, Zarghami N, et al. NAC effects on metabolic syndrome: RCT. Complement Ther Med 2022;71:102898.
Pereira L, et al. NAC attenuates atherosclerosis progression in aging LDLr-/- mice. Atherosclerosis 2022;357:41–51.
Wilmink HW, Stroes ES, Erkelens WD, et al. NAC prevents post-methionine endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999;19(12):2862–2866. PMID 10479652.

Connections

↑ Back to Table of Contents

Featured Videos

NAC and Cardiovascular Health

Nitric Oxide, Nitrates, and Thiol Donors

NACIAM Trial — NAC in Acute MI